Previous close | 3,644.27 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 4,048.97 - 4,048.97 |
52-week range | 3,249.12 - 4,073.04 |
Volume | |
Avg. volume | 53 |
Market cap | 187.085B |
Beta (5Y monthly) | 1.44 |
PE ratio (TTM) | 25.48 |
EPS (TTM) | 142.52 |
Earnings date | 07 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WILMINGTON, Mass., May 09, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023.
Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Sotera Health (SHC) delivered earnings and revenue surprises of -7.14% and 2.57%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?